

# N-Derivatives of (Z)-methyl 3-(4-oxo-2-thioxothiazolidin-5-ylidene) methyl)-1H-indole-2-carboxylates as antimicrobial agents. *In silico* and *in vitro* evaluation.

Anthi Petrou<sup>1</sup>, Athina Geronikaki<sup>1\*</sup>, Victor Kartsev<sup>2</sup>, Antonis Kousaxidis<sup>1</sup>, Alik Papadimitriou-Tsantarliotou<sup>3</sup>, Marina Kostic<sup>4</sup>, Marija Ivanov<sup>4</sup>, Marina Sokovic<sup>4</sup>, Ioannis Nikolaou<sup>1</sup>, Ioannis S. Vizirianakis<sup>3,5</sup>

<sup>1</sup> Department of Pharmaceutical Chemistry, School of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece

<sup>2</sup> InterBioScreen, 142432 Chernogolovka, Moscow Region, Russia

<sup>3</sup> Laboratory of Pharmacology, School of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, Greece

<sup>4</sup> Mycological Laboratory, Department of Plant Physiology, Institute for Biological Research, Siniša, Stankovic-National Institute of Republic of Serbia, University of Belgrade, Bulevar Despota Stefana 142, 11000 Belgrade, Serbia

<sup>5</sup> Department of Life and Health Sciences, University of Nicosia, Nicosia, Cyprus

\* Correspondence: geronik@pharm.auth.gr

**Table S1.** Prediction of organ toxicity and toxicity end points for compounds 1-17.

Comp.	Organ toxicity			Toxicity end points			
	Cardiotoxicity	Hepatotoxicity	Carcinogenicity	Immunotoxicity	Mutagenicity	Cytotoxicity	Phospholipidosis
1	Inactive (0.79)	Inactive (0.68)	Inactive (0.62)	Inactive(0.55)	Inactive (0.74)	Inactive(0.64)	Inactive (0.99)
2	Inactive (0.75)	Active (0.56)	Inactive (0.63)	Inactive (0.97)	Inactive (0.55)	Inactive (0.64)	Inactive (0.89)
3	Inactive (0.93)	Active (0.59)	Inactive (0.61)	Active (0.61)	Inactive (0.54)	Inactive(0.61)	Inactive (0.89)
4	Inactive (0.93)	Active (0.60)	Inactive (0.60)	Active(0.72)	Inactive (0.53)	Inactive(0.64)	Inactive (0.89)
5	Inactive (0.60)	Inactive (0.66)	Inactive (0.57)	Active (0.88)	Inactive (0.69)	Inactive (0.65)	Inactive (0.81)
6	Inactive (0.93)	Active (0.52)	Inactive (0.56)	Inactive (0.76)	Inactive (0.58)	Inactive (0.65)	Inactive (0.93)
7	Inactive (0.84)	Inactive (0.50)	Inactive (0.58)	Inactive (0.76)	Inactive (0.61)	Inactive (0.62)	Inactive (0.89)
8	Inactive (0.84)	Active (0.55)	Inactive (0.66)	Active (0.64)	Inactive (0.64)	Inactive (0.70)	Inactive (0.99)
9	Inactive (0.84)	Active (0.51)	Inactive (0.62)	Active (0.77)	Inactive (0.71)	Inactive (0.63)	Inactive (0.99)
10	Inactive (0.93)	Active (0.59)	Inactive (0.62)	Active (0.84)	Inactive (0.58)	Inactive (0.67)	Inactive (0.89)
11	Inactive (0.84)	Inactive (0.53)	Inactive (0.63)	Inactive (0.82)	Inactive (0.69)	Inactive (0.64)	Inactive (0.99)
12	Inactive (0.84)	Inactive (0.54)	Inactive (0.68)	Inactive (0.88)	Inactive (0.63)	Inactive (0.67)	Inactive (0.99)
13	Inactive (0.93)	Active (0.57)	Inactive (0.60)	Active (0.98)	Inactive (0.59)	Inactive (0.70)	Inactive (0.81)
14	Inactive (0.84)	Inactive (0.52)	Inactive (0.63)	Active (0.78)	Inactive (0.70)	Inactive (0.63)	Inactive (0.99)
15	Inactive (0.93)	Active (0.56)	Inactive (0.63)	Inactive (0.54)	Inactive (0.58)	Inactive (0.73)	Inactive (0.89)
16	Inactive (0.93)	Active (0.51)	Inactive (0.59)	Active (0.81)	Inactive (0.57)	Inactive (0.65)	Inactive (0.93)
17	Inactive (0.79)	Active (0.59)	Inactive (0.63)	Active (0.79)	Inactive (0.71)	Inactive (0.63)	Inactive (0.99)

Number in brackets indicate possibilities. Cardiotoxicity is referred to the probability of inhibition of the inward rectifying voltage gated potassium channel in the heart encoded by the human ether-a-go-go related gene (hERG).


**Table S2.** Prediction of adverse outcomes according to TOX21 of compounds 1-17.

Comp.	Tox21-Nuclear receptor signalling pathways							Tox21-Stress response pathways				
	AhR	AR	AR-LBD	ARO	ER	ER-LBD	PPAR $\gamma$	NRF2/ARE	HSE	MMP	p53	ATAD5
1	Inactive (0.77)	Inactive (0.98)	Inactive (0.97)	Inactive (0.93)	Inactive (0.87)	Inactive (0.95)	Inactive (0.81)	Inactive (0.85)	Inactive (0.85)	Inactive (0.85)	Inactive (0.81)	Inactive (0.90)
2	Inactive (0.61)	Inactive (0.95)	Inactive (0.97)	Inactive (0.81)	Inactive (0.76)	Inactive (0.92)	Inactive (0.81)	Inactive (0.90)	Inactive (0.90)	Inactive (0.54)	Inactive (0.75)	Inactive (0.71)
3	Inactive (0.60)	Inactive (0.92)	Inactive (0.97)	Inactive (0.84)	Inactive (0.73)	Inactive (0.92)	Inactive (0.82)	Inactive (0.89)	Inactive (0.89)	Inactive (0.51)	Inactive (0.71)	Inactive (0.75)
4	Inactive (0.63)	Inactive (0.94)	Inactive (0.97)	Inactive (0.83)	Inactive (0.72)	Inactive (0.90)	Inactive (0.81)	Inactive (0.91)	Inactive (0.91)	Inactive (0.51)	Inactive (0.70)	Inactive (0.75)
5	Inactive (0.78)	Inactive (0.95)	Inactive (0.93)	Inactive (0.91)	Inactive (0.87)	Inactive (0.94)	Inactive (0.82)	Inactive (0.91)	Inactive (0.91)	Inactive (0.75)	Inactive (0.82)	Inactive (0.94)
6	Inactive (0.82)	Inactive (0.95)	Inactive (0.95)	Inactive (0.90)	Inactive (0.87)	Inactive (0.94)	Inactive (0.88)	Inactive (0.92)	Inactive (0.92)	Inactive (0.69)	Inactive (0.89)	Inactive (0.94)
7	Inactive (0.65)	Inactive (0.98)	Inactive (0.96)	Inactive (0.93)	Inactive (0.84)	Inactive (0.95)	Inactive (0.84)	Inactive (0.91)	Inactive (0.91)	Inactive (0.79)	Inactive (0.81)	Inactive (0.83)
8	Inactive (0.63)	Inactive (0.97)	Inactive (0.97)	Inactive (0.87)	Inactive (0.79)	Inactive (0.88)	Inactive (0.87)	Inactive (0.89)	Inactive (0.89)	Inactive (0.65)	Inactive (0.79)	Inactive (0.91)
9	Inactive (0.78)	Inactive (0.98)	Inactive (0.97)	Inactive (0.90)	Inactive (0.84)	Inactive (0.90)	Inactive (0.79)	Inactive (0.85)	Inactive (0.85)	Inactive (0.82)	Inactive (0.82)	Inactive (0.87)
10	Inactive (0.65)	Inactive (0.96)	Inactive (0.96)	Inactive (0.87)	Inactive (0.71)	Inactive (0.83)	Inactive (0.78)	Inactive (0.89)	Inactive (0.89)	Inactive (0.54)	Inactive (0.73)	Inactive (0.82)
11	Inactive (0.72)	Inactive (0.98)	Inactive (0.97)	Inactive (0.93)	Inactive (0.89)	Inactive (0.95)	Inactive (0.80)	Inactive (0.86)	Inactive (0.86)	Inactive (0.83)	Inactive (0.84)	Inactive (0.79)
12	Inactive (0.64)	Inactive (0.97)	Inactive (0.97)	Inactive (0.91)	Inactive (0.82)	Inactive (0.92)	Inactive (0.88)	Inactive (0.90)	Inactive (0.90)	Inactive (0.67)	Inactive (0.79)	Inactive (0.89)
13	Inactive (0.63)	Inactive (0.95)	Inactive (0.95)	Inactive (0.88)	Inactive (0.72)	Inactive (0.88)	Inactive (0.86)	Inactive (0.89)	Inactive (0.89)	Inactive (0.53)	Inactive (0.75)	Inactive (0.84)
14	Inactive (0.78)	Inactive (0.98)	Inactive (0.96)	Inactive (0.89)	Inactive (0.84)	Inactive (0.89)	Inactive (0.81)	Inactive (0.86)	Inactive (0.86)	Inactive (0.82)	Inactive (0.83)	Inactive (0.86)
15	Inactive (0.58)	Inactive (0.97)	Inactive (0.96)	Inactive (0.89)	Inactive (0.80)	Inactive (0.93)	Inactive (0.89)	Inactive (0.91)	Inactive (0.91)	Inactive (0.65)	Inactive (0.77)	Inactive (0.88)
16	Inactive (0.84)	Inactive (0.97)	Inactive (0.93)	Inactive (0.91)	Inactive (0.80)	Inactive (0.90)	Inactive (0.90)	Inactive (0.91)	Inactive (0.91)	Inactive (0.73)	Inactive (0.89)	Inactive (0.93)
17	Inactive (0.79)	Inactive (0.98)	Inactive (0.96)	Inactive (0.94)	Inactive (0.89)	Inactive (0.95)	Inactive (0.80)	Inactive (0.89)	Inactive (0.89)	Inactive (0.85)	Inactive (0.81)	Inactive (0.84)


(1) Aryl hydrocarbon Receptor, (2) Androgen Receptor, (3) Androgen Receptor Ligand Binding Domain, (4) Aromatase, (5) Estrogen Receptor Alpha, (6) Estrogen Receptor Ligand Binding Domain, (7) Peroxisome Proliferator Activated Receptor Gamma, (8) Nuclear factor (erythroid-derived 2)-like 2/antioxidant responsive element, (9) Heat shock factor response element, (10) Heat shock factor response element, (11) Phosphoprotein (Tumor Suppressor) p53, (12) ATPase family AAA domain-containing protein 5

## <sup>1</sup>H-NMR and <sup>13</sup>C-NMR of compounds

### Compound 1




CARBON\_01  
1\_6s-54377







# Compound 2




CARBON\_01  
2\_45217




# Compound 3




CARBON\_01




# Compound 4




CARBON\_01  
6s-51045



# Compound 5




CARBON\_01  
6S-48054








# Compound 6




CARBON\_01  
6s\_49880




# Compound 7




CARBON\_01  
6s-49428-




# Compound 8




CARBON\_01  
8\_6s-49299



# Compound 9




CARBON\_01






# Compound 10




CARBON\_01  
6s-53348-




# Compound 11

F33978




CARBON\_01  
11-comp




# Compound 12


F33979




CARBON\_01  
6S-54131-17COMP



Compound 13




CARBON\_01  
6s-63825-copm17






# Compound 14

F30428




CARBON\_01  
52686-




# Compound 15


F30429




CARBON\_01




# Compound 16



CARBON\_01



# Compound 17



CARBON\_01

